P. Becker

G. Pihan, S. Heard, P. Becker, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment

P. Becker, Pamela S. Becker, 2012, TheScientificWorldJournal.

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

P. Richardson, R. Perez, P. Sabbatini, 2014 .

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

E. Estey, B. Wood, F. Appelbaum, 2013 .

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

B. Smith, P. Sabbatini, J. Altman, 2014 .

Variables to predict engraftment of umbilical cord blood into immunodeficient mice: usefulness of the non‐obese diabetic–severe combined immunodeficient assay

P. Quesenberry, K. Ballen, C. Hsieh, 2001, British journal of haematology.

Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD‐scid mice

J. Wuu, P. Quesenberry, K. Ballen, 2000, British journal of haematology.

A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma

D. Esseltine, S. Jagannath, D. Vesole, 2007 .

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Michael D. Robbins, J. Laubach, P. Richardson, 2019, Clinical Cancer Research.

90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

B. Sandmaier, J. Pagel, J. Rajendran, 2020, Bone Marrow Transplantation.

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma

P. Hari, R. Storb, B. Sandmaier, 2018, Haematologica.

KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation.

D. Coffey, P. Becker, A. Cowan, 2020, Clinical lymphoma, myeloma & leukemia.

Engraftment of normal murine marrow into nonmyeloablated host mice.

P. Quesenberry, P. Becker, F. Stewart, 1994, Blood cells.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

A. Letai, Wan-Jen Hong, M. Konopleva, 2019, Blood.

Safety and Cost of Hyperhydration for the Prevention of Hemorrhagic Cystitis in Bone Marrow Transplant Recipients

W. Levy, P. Quesenberry, K. Ballen, 1999, Oncology.

The Current Status of Gene Therapy in Autologous Transplantation

P. Becker, 2005, Acta Haematologica.

A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

D. Maloney, T. Gooley, O. Press, 2016, Bone Marrow Transplantation.

Envelope-Specific Adaptive Immunity following Transplantation of Hematopoietic Stem Cells Modified with VSV-G Lentivirus

H. Kiem, C. Peterson, P. Becker, 2020, Molecular therapy. Methods & clinical development.

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy

R. Larson, H. Kantarjian, P. Fenaux, 2017, British journal of haematology.

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

Yow-Ming C Wang, H. Kantarjian, P. Fenaux, 2011, Cancer.

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

R. Larson, H. Kantarjian, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study

R. Larson, H. Kantarjian, P. Fenaux, 2007 .

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility

M. Sorror, M. Othus, R. Walter, 2020, Haematologica.

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

E. Estey, F. Appelbaum, R. Sandhu, 2012 .

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

R. Larson, H. Kantarjian, P. Fenaux, 2007 .

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models

E. Estey, M. Sorror, B. Sandmaier, 2016 .

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study

E. Estey, M. Othus, R. Walter, 2017, Leukemia & lymphoma.

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy

E. Estey, J. Abkowitz, F. Appelbaum, 2015, Leukemia.

Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2022, Leukemia.

Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia

E. Estey, B. Sandmaier, F. Appelbaum, 2015, Haematologica.

Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

E. Estey, M. Othus, R. Walter, 2016, Leukemia & lymphoma.

Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay

Chris P. Miller, Su-In Lee, K. Y. Yeung, 2013 .

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

R. Larson, A. Yang, H. Kantarjian, 2009 .

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.

E. Estey, F. Appelbaum, R. Walter, 2020, Blood advances.

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2019, Leukemia.

Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.

I. Bernstein, E. Estey, F. Appelbaum, 2016, The Lancet. Haematology.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high‐risk MDS

E. Estey, B. Wood, J. Singer, 2016, British journal of haematology.

Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia

E. Estey, B. Storer, D. Stirewalt, 2011, British journal of haematology.

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

E. Estey, B. Storer, D. Stirewalt, 2010 .

Immunofluorescence Characterization of Key Extracellular Matrix Proteins in Murine Bone Marrow In Situ

S. Nilsson, P. Quesenberry, M. Dooner, 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

B. Storer, S. Petersdorf, A. Ramakrishnan, 2007 .

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation

D. Coffey, P. Becker, A. Cowan, 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Multiple myeloma and Gaucher genes

P. Becker, B. Rosenbloom, N. Weinreb, 2009, Genetics in Medicine.

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome.

J. Cortes, J. Pagel, C. Jung, 2020, Blood advances.

Panobinostat: a review of trial results and future prospects in multiple myeloma

N. Burwick, P. Becker, W. Bensinger, 2015, Expert review of hematology.

Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.

Ankita Patel, F. Appelbaum, K. Eaton, 2015, American journal of clinical pathology.

Gene therapy for Fanconi anemia: one step closer to the clinic.

J. Tolar, J. Bueren, H. Hanenberg, 2012, Human gene therapy.

Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities

H. Kiem, G. Trobridge, P. Becker, 2012, Journal of Molecular Medicine.

VLA-4 Function and Prognosis in Acute Myeloid Leukemia

F. Appelbaum, P. Becker, 2015 .

Adhesion receptor expression by CD34+ cells from peripheral blood or bone marrow grafts: correlation with time to engraftment.

K. Ballen, H. Valinski, P. Becker, 2006, Experimental hematology.

Homing of purified murine lymphohematopoietic stem cells: a cytokine-induced defect.

S. Nilsson, P. Quesenberry, M. Dooner, 2002, Journal of hematotherapy & stem cell research.

The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells.

P. Quesenberry, G. Nowakowski, H. Valinski, 2001, Experimental hematology.

Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.

M. Othus, R. Walter, P. Becker, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2020, Leukemia & lymphoma.

Need for routine examination of left ventricular ejection fraction in patients with AML

E. Estey, M. Sorror, R. Walter, 2019, Leukemia.

Hematopoietic stem cell gene therapy for inherited bone marrow disorders: Past accomplishments and continued challenges

P. Becker, 2002, Journal of cellular biochemistry. Supplement.

malignancy infusion may induce remission in patients with refractory hematologic Low-dose total body irradiation followed by allogeneic lymphocyte

W. Levy, F. Chiafari, P. Quesenberry, 2013 .

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS).

H. Kantarjian, P. Fenaux, M. Sekeres, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paradoxical worsening of anti–myelin‐associated glycoprotein polyneuropathy following rituximab

M. Weiss, P. Becker, 2014, Muscle & nerve.

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma

N. Burwick, P. Becker, W. Bensinger, 2016, Blood Cancer Journal.

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center

R. Storb, B. Sandmaier, D. Maloney, 2012, Bone Marrow Transplantation.

Immune defects in a mouse model of Fanconi anaemia

B. Wood, E. Goren, P. Becker, 2012, British journal of haematology.

Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting.

David A. Williams, C. von Kalle, J. Wagner, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma

N. Burwick, P. Becker, W. Bensinger, 2014, Bone Marrow Transplantation.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

E. Estey, M. Othus, R. Walter, 2018, Haematologica.

Autologous stem-cell transplantation can be performed safely without the use of blood-product support.

B. Yeap, K. Ballen, D. Henry, 2004, Journal of Clinical Oncology.

Multiple Myeloma: Diagnosis and Orthopaedic Implications

E. Conrad, P. Becker, T. Scharschmidt, 2011, The Journal of the American Academy of Orthopaedic Surgeons.

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

E. Estey, J. Abkowitz, B. Wood, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controversies Regarding Use of Myeloid Growth Factors in Leukemia.

P. Becker, Pamela S Becker, Jacqueline N Poston, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm

P. Becker, R. Cassaday, M. Ulrickson, 2017, American journal of hematology.

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.

E. Rasmussen, M. Grunwald, E. Wang, 2019, Blood advances.

Gene Therapy for Fanconi Anemia in Seattle: Clinical Experience and Next Steps

H. Kiem, P. Becker, J. Adair, 2016 .

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

N. Burwick, P. Becker, W. Bensinger, 2015, Bone Marrow Transplantation.

Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function.

E. Estey, J. Abkowitz, Z. Duan, 2022, Cell stem cell.

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

M. Erlander, S. Silberman, G. Schiller, 2020, Clinical Cancer Research.

Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer.

Chung-Cheng Hsieh, Pagona Lagiou, D. Trichopoulos, 2005, Cancer research.

Stem Cells and Prenatal Origin of Breast Cancer

P. Quesenberry, K. Ballen, P. Lagiou, 2004, Cancer Causes & Control.

Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A

H. Kiem, P. Becker, Kevin G. Haworth, 2018, Haematologica.

Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities

H. Kiem, G. Trobridge, P. Becker, 2012, Journal of Molecular Medicine.

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

P. Hari, M. Pasquini, M. Qazilbash, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell homing: rolling, crawling, and nesting.

P. Quesenberry, P. Becker, Peter J. Quesenberry, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Cancer- and chemotherapy-induced anemia.

M. Millenson, C. Cleeland, D. Cella, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.

Chris P. Miller, D. Haussler, Su-In Lee, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Gene transfer to ankyrin-deficient bone marrow corrects spherocytosis in vitro.

M. Debatis, B. Forget, P. Gallagher, 2000, Experimental hematology.

Physical and physiological plasticity of hematopoietic stem cells.

P. Quesenberry, M. Dooner, P. Becker, 2001, Blood cells, molecules & diseases.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J. Armitage, H. Rugo, G. Lyman, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

The Role of Biosimilars.

A. Zelenetz, P. Becker, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.

J. A. Maguire, Matthew R Hart, P. Gadue, 2021, Blood advances.

Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

E. Estey, M. Sorror, B. Storer, 2017, JAMA oncology.

Stem Cell Engraftment Strategies

P. Quesenberry, M. Dooner, K. Ballen, 2001, Annals of the New York Academy of Sciences.

Stem cell engraftment and cell cycle phenotype

S. Nilsson, H. Ramshaw, P. Quesenberry, 1999, Leukemia.

Gene transfer in the nonmyeloablated host.

P. Quesenberry, P. Becker, 1999, Progress in experimental tumor research.

Unsupervised discovery of dynamic cell phenotypic states from transmitted light movies

H. Kueh, R. Monnat, P. Becker, 2021, bioRxiv.

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.

E. Estey, M. Sorror, B. Sandmaier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloid growth factors.

J. Armitage, M. Dwyer, H. Rugo, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

S. Jagannath, S. Girish, A. Solinger, 2006 .

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

A. Letai, C. Dinardo, K. Pratz, 2019, Blood.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2017, Haematologica.

A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

P. Marlton, D. DeAngelo, J. Liesveld, 2019, Journal of Clinical Oncology.

Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma.

Joseph D Tariman, D. Berry, K. Schepp, 2014, Cancer treatment communications.

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

A. Zelenetz, D. Brander, S. Schuster, 2018, Blood.

Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept

E. Estey, H. Deeg, B. Storer, 2010, British journal of haematology.

Giant platelets with abnormal surface glycoproteins: a new familial disorder associated with mitral valve insufficiency.

P. Becker, L. Clavell, D. Beardsley, 1998, Journal of pediatric hematology/oncology.

CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch

P. Becker, S. Ciurea, S. O'Brien, 2022, American journal of hematology.

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms

E. Estey, F. Appelbaum, M. Othus, 2018, Leukemia.

Review Article Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment 1. Adhesion and Leukemia Biology

P. Becker, 2022 .

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

B. Wood, D. Maloney, F. Appelbaum, 2018, Blood.

Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).

A. Letai, O. Frankfurt, C. Dinardo, 2018 .

Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia

E. Estey, R. Walter, P. Becker, 2021, Cancer.

Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma.

P. Becker, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

D. Maloney, J. Pagel, M. Shadman, 2016, Leukemia & lymphoma.

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD

B. Wood, B. Sandmaier, P. Becker, 2018, American journal of hematology.

Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma

P. Becker, E. Libby, L. Holmberg, 2019, Acta Haematologica.

Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.

D. Coffey, P. Becker, A. Cowan, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin

P. Becker, W. Bensinger, L. Holmberg, 2017, Acta Haematologica.

Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study

B. Storer, S. Petersdorf, A. Ramakrishnan, 2010, British journal of haematology.

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

Chris P. Miller, Scott M. Lundberg, Su-In Lee, 2018, Nature Communications.

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML

E. Estey, M. Sorror, F. Appelbaum, 2020, Cancer medicine.

Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.

Brendan F. Kohrn, E. Estey, K. Loeb, 2022, Leukemia research.

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

S. Jagannath, D. Vesole, B. Durie, 2010, British journal of haematology.

Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia

E. Estey, J. Abkowitz, B. Wood, 2020, Leukemia & lymphoma.

Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia

E. Estey, B. Storer, F. Appelbaum, 2013, Haematologica.

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

A. Carson, E. Estey, L. Loeb, 2020 .

Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney

S. Akilesh, P. Becker, K. Edlefsen, 2020, Leukemia.

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia

E. Estey, J. Radich, R. Walter, 2023, Leukemia & lymphoma.

A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

S. Jagannath, B. Ewald, R. Maziarz, 2012, British journal of haematology.

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2019, Blood.

Marrow Stem Cells Shift Gene Expression and Engraftment Phenotype with Cell Cycle Transit

S. Weissman, P. Quesenberry, M. Dooner, 2003, The Journal of experimental medicine.

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

G. Marcucci, I. Aldoss, P. Curtin, 2023, American journal of hematology.

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

E. Estey, J. Radich, P. Becker, 2018, Blood.

Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid

E. Estey, J. Abkowitz, K. Loeb, 2016, British journal of haematology.

JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?

P. Becker, Bart L Scott, B. Scott, 2015, JAMA oncology.

Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML).

E. Estey, J. Abkowitz, F. Appelbaum, 2010, Leukemia research reports.

Outcome of Multiple Myeloma Patients Treated with Carrd-PACE Chemomobilization: A Single-Center Experience

D. Coffey, M. Shadman, P. Becker, 2016 .

Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector

J. Wagner, A. Shimamura, H. Kiem, 2010, Gene Therapy.

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia

I. Shmulevich, R. Monnat, Boris Aguilar, 2023, bioRxiv.

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION

A. Zelenetz, E. L. Luning Prak, D. Brander, 2019, Hematological Oncology.

Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia.

J. Bueren, H. Kiem, C. D. Heredia, 2017, Current gene therapy.

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.

E. Estey, B. Wood, F. Appelbaum, 2009 .

Tocilizumab for Cytokine Release Syndrome Management after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Case of Chemotherapy-Refractory, RAS-Mutated Chronic Myelomonocytic Leukemia Responsive to Single-Agent Trametinib Based on Results From a High-Throughput Drug Screen

T. Martins, P. Becker, S. Chien, 2020 .

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

T. Gooley, D. Coffey, P. Becker, 2019, Blood.

Relation between measurable residual disease and morphologic relapse in AML.

E. Estey, M. Othus, R. Walter, 2020 .

High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia

A. Carson, Su-In Lee, E. Estey, 2018, Blood.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

E. Estey, J. Pagel, R. Walter, 2015, American journal of hematology.

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.

E. Estey, M. Sorror, B. Sandmaier, 2022, Blood.

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

E. Estey, F. Appelbaum, J. Pagel, 2014, British Journal of Haematology.

Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

S. Schuster, A. Mato, M. Shadman, 2017 .

A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

E. Estey, S. Meshinchi, D. Stirewalt, 2013, British journal of haematology.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after ‘Day 14’ without further therapy in acute myeloid leukemia

E. Estey, F. Appelbaum, M. Othus, 2017, Leukemia & lymphoma.

Evaluating surface erythropoietin receptor in multiple myeloma

N. Burwick, C. Miller, P. Becker, 2012, Leukemia.

Radiolabel-transfer cross-linking demonstrates that protein 4.1 binds to the N-terminal region of beta spectrin and to actin in binary interactions.

M. Schwartz, J. Morrow, S. Lux, 1990, European journal of biochemistry.

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

E. Estey, M. Othus, R. Walter, 2023, Leukemia.

The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia.

E. Estey, F. Appelbaum, J. Pagel, 2013, Blood.

G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

E. Estey, J. Abkowitz, F. Appelbaum, 2015, American journal of hematology.

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

E. Estey, J. Abkowitz, M. Othus, 2023, Blood Advances.

E. Estey, E. Pogosova-Agadjanyan, M. Othus, 2017, Leukemia.

Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy.

W. Levy, P. Quesenberry, T. Fitzgerald, 2002, Blood.

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

E. Estey, B. Storer, F. Appelbaum, 2008 .

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

E. Estey, B. Storer, F. Appelbaum, 2009 .

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes.

J. Abkowitz, David Wu, E. Konnick, 2019, Blood.

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

E. Estey, M. Sorror, B. Sandmaier, 2018, Blood.

Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML

E. Estey, F. Appelbaum, J. Pagel, 2013 .

Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study

J. Cortes, J. Liesveld, D. Johns, 2011 .

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

P. Marlton, D. DeAngelo, J. Liesveld, 2018, Blood.

Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation

E. Estey, R. Moon, F. Appelbaum, 2013 .